Skip to playerSkip to main content
  • 7 weeks ago
Medical professionals at Charité – Universitätsmedizin Berlin have successfully utilized CAR T-cell therapy, originally designed for cancer, to induce remission in severe, treatment-resistant rheumatoid arthritis for the first time. A recent small-scale study published in Nature Medicine revealed that all six participants experienced a significant decrease in disease activity, with three individuals no longer requiring arthritis medications after a follow-up period of up to one year. Researchers suggest that the therapy may function by eliminating the immune cells responsible for the disease and effectively reestablishing a portion of the immune system. However, further extensive trials are necessary before it can be broadly implemented.
Disclosure:
This video contains stock footage and content created or enhanced using AI-assisted tools.

ai-generated

Category

🗞
News
Transcript
00:00A treatment best known for fighting cancer just put severe rheumatoid arthritis into remission for the first time.
00:06Doctors at Charité, a major hospital in Berlin,
00:09treated six patients with severe, treatment-resistant rheumatoid arthritis using CAR T-cell therapy,
00:15a method that reprograms a patient's own immune cells in the lab to hunt down disease-driving cells.
00:21In the trial, published in Nature Medicine, every single patient saw their disease activity drop substantially.
00:28By the end of the follow-up period, which lasted up to a year,
00:32three of the six patients no longer needed any arthritis medication at all.
00:36Researchers believe the therapy works by clearing out harmful immune cells
00:40and effectively rebooting part of the immune system.
00:43It's a remarkable result for patients whose disease hadn't responded to any existing treatment,
00:48though scientists caution that much larger trials are still needed
00:52before this becomes a real option for people living with the disease.
00:55Disclosure. This video contains stock footage and content created or enhanced using AI-assisted tools.
01:01See you all tonight.

Recommended